Ariana® Pharma and CTCLS Sign Japanese Distribution Agreement
News Nov 01, 2012
Ariana Pharma has announced the signing of an exclusive Japanese distribution agreement with CTC Laboratory Systems Corporation (CTCLS), the Japanese supplier of services for R&D solutions.
CTCLS will distribute Ariana’s KEM® data analytics software and services technology to Japanese markets. Ariana selected CTCLS as its Japanese distribution partner because of the company’s dominant presence in Japan.
CTCLS is a leading R&D service provider, offering total solutions to major industries and specializing in the pharmaceutical sector.
Ariana’s KEM®, or Knowledge Extraction and Management, is a novel, association rules-based (non-statistical) data-analytical technology that finds patient responder sub-populations and biomarker signatures that statistical methods are unable to detect.
In the life science industry, KEM saves sponsors both time and money by optimizing clinical trial inclusion/exclusion criteria thereby lowering the number of patients needed to reach clinical endpoints.
“In the first half of 2012, we expanded west from Europe to launch our US office, and now we’re progressing into the Far East with the CTCLS distribution agreement,” said Dr. Mohammad Afshar, president and CEO of Ariana Pharma.
Dr. Afshar continued, “This deal with CTCLS will provide an excellent entry into Asia and the world's third largest biotechnology market. We expect the ongoing growth of Japanese companies in medicine development, diagnostics and biomarker studies will further increase demand for Ariana’s KEM® software.”
“After having invested resources in acquiring equipment and establishing processes to generate data, our clients are now focusing on technologies that extract valuable information and exploit data to the fullest extent,” said Hideki Negishi, president and CEO of CTCLS.
Negishi continued, “CTCLS is selecting leading technologies in pharmaceutical and manufacturing areas to deliver to the Japanese markets. We are confident that the application of KEM will accelerate developments in these industries.”
Possible Biomarker to Identify Who Would Benefit from ImmunotherapyNews
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments. In a new study, researchers examined tissue samples from melanoma and ovarian cancer patients treated with immunotherapies and found a link between the percentage of antigen-presenting cells expressing PD-L1 and an objective clinical response to treatment.READ MORE